ALACHUA, Fla., May 9 /PRNewswire-FirstCall/ -- Regeneration Technologies, Inc. (RTI) , a leading processor of orthopedic, cardiovascular and other biologic implants, announced today that the company’s revenues were $18.4 million for the first quarter of 2006, an increase of 23 percent compared to $15.0 million for the first quarter 2005.
For the first quarter ended March 31, 2006, the company reported net loss of $1.3 million and net loss per diluted share of $0.04, compared to net loss of $1.3 million and net loss per diluted share of $0.05 for the first quarter 2005. Excluding a $678,000 charge related to stock-based compensation, the adjusted net loss for the first quarter of 2006 was $782,000.
First Quarter 2006 Analysis
Spinal Constructs: Revenues from distribution of spinal implants were $9.2 million for the first quarter, compared to $5.9 million in the previous year, representing an increase of 57 percent. The increase in revenues relates to higher volumes of our assembled cervical grafts and increased lumbar orders to maintain exclusivity for several products by our largest distributor. The revenues from spinal implants have remained relatively flat for the past four quarters.
Bone Graft Substitutes: The bone graft substitutes revenue category consists of all moldable and flowable bone pastes, as well as all chips and cubes. These implants were previously classified within spinal implants and general orthopedics. Revenues from distribution of bone graft substitutes were $3.8 million for the first quarter, compared to $3.6 million for the previous year, representing an increase of 5 percent. The increase in revenues was attributable to improved performance by our direct distribution network both domestically and internationally, which offset a decline in orders by our largest distributor.
Sports Medicine: Revenues from distribution of sports medicine implants were $3.2 million for first quarter, compared to $2.2 million for the previous year, representing an increase of 42 percent. The increase was principally the result of the majority of these products being distributed through our direct distribution compared to an independent distributor in 2005.
Cardiovascular: Revenues from distribution of cardiovascular implants were $1.3 million for the first quarter, compared to $2.1 million for the previous year, representing a decrease of 39 percent. The primary reason for the decreased revenue was lower cardiovascular recoveries during the quarter. Demand for these life-saving implants remains high.
General Orthopedic: Revenues from general orthopedic implants were $277,000 for the first quarter, compared to $212,000 for the first quarter of the previous year, representing an increase of 31 percent. An increase in unit volume during the quarter was a result of these implants being distributed through our direct network of representatives.
During the first quarter of 2006 the company continued to make progress on its key strategies:
Optimizing distribution - During the first quarter, the company held its first national distributors’ meeting where representatives received in-depth training on this year’s new implants, including our Sterling(R) line of xenograft products, BioSet(R) Demineralized Bone Matrix and our assembled tendon implants. During the quarter the total number of domestic representatives was increased from 35 to 80.
Increased focus on research and development - During the first quarter, the company launched the Crescent(TM) lumbar allograft to its largest distributor. The new Adjustable Bone Tendon Bone (BTB) allograft was also completed for a second quarter launch.
Launch and growth of Sterling(R) product line - One of the highlights of the quarter was the annual meeting of the American Association of Orthopaedic Surgeons (AAOS), where RTI officially launched the Sterling line of implants. Hundreds of surgeons were introduced to the new product line, which was very favorably received.
Conference Call
RTI will hold a live conference call and simultaneous audio web cast on Tuesday, May 9, 2006 at 9:00 a.m. ET to discuss first quarter results. The conference call can be accessed by dialing 888-390-0675, passcode RTIXQ ONE. The web cast can be accessed through the investor section of RTI’s web site at http://www.rtix.com . A telephone replay of the call will be available through June 9, 2006 and can be accessed by calling 800-839-4890; the replay will also be available at http://www.rtix.com .
About Regeneration Technologies, Inc.
RTI processes allograft and xenograft tissue into shaped implants for use in orthopedic, cardiovascular and other surgeries with a commitment to science, safety and innovation.
RTI also holds the patents on BioCleanse(R), the only proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than 675,000 allograft implants sterilized with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks and was named a 2004 Technology Pioneer by the World Economic Forum.
Except for historical information, any statements made in this press release about the company’s anticipated financial results, growth rates, new product introductions, future operational improvements and results, regulatory approvals or changes to the company’s agreements with its distributors are forward-looking statements subject to risks and uncertainties, such as those described in the company’s public filings on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s web site at http://www.rtix.com or the SEC’s web site at http://www.sec.gov .
REGENERATION TECHNOLOGIES, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (In thousands, except share and per share data) Three Months Ended March 31, 2006 2005 Revenues: Fees from tissue distribution $17,716 $14,017 Other revenues 709 953 Total net revenues 18,425 14,970 Costs of processing and distribution 12,932 10,347 Gross profit 5,493 4,623 Operating Expenses 7,497 6,659 Operating loss (2,004) (2,036) Net interest income (expense) 17 (173) Loss before income tax benefit (1,987) (2,209) Income tax benefit 691 959 Net loss $(1,296) $(1,250) Net loss per common share - basic $(0.04) $(0.05) Net loss per common share - diluted $(0.04) $(0.05) Weighted average shares outstanding - basic 29,711,763 26,732,603 Weighted average shares outstanding - diluted 29,711,763 26,732,603 REGENERATION TECHNOLOGIES, INC. AND SUBSIDIARIES Revenues (In thousands) Three Months Ended March 31, 2006 2005 Fees from tissue distribution: Spinal constructs $9,180 $5,845 Bone graft substitutes 3,782 3,598 Sports medicine 3,188 2,243 Cardiovascular 1,289 2,119 General orthopedic 277 212 Other revenues 709 953 Total $18,425 $14,970 REGENERATION TECHNOLOGIES, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands) March 31, December 31, Assets 2006 2005 Current Assets: Cash and cash equivalents $24,991 $25,559 Accounts receivable - net 6,509 9,021 Inventories 38,269 38,534 Other current assets 12,197 12,181 Total current assets 81,966 85,295 Property, plant and equipment - net 43,830 44,527 Other assets 12,308 12,440 Total assets $138,104 $142,262 Liabilities and Stockholders’ Equity Current Liabilities: Accounts payable $7,751 $7,123 Other current liabilities 6,467 8,575 Total current liabilities 14,218 15,698 Other liabilities 6,620 8,751 Total liabilities 20,838 24,449 Total stockholders’ equity 117,266 117,813 Total liabilities and stockholders’ equity $138,104 $142,262 REGENERATION TECHNOLOGIES, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (In thousands) Three Months Ended March 31, 2006 2005 Cash flows from operating activities: Net loss $(1,296) $(1,250) Adjustments to reconcile net loss to net cash provided by (used) in operating activities: Depreciation and amortization expense 1,251 1,106 Amortization of deferred financing costs 43 45 Change in working capital 39 (2,852) Other (12) (1,092) Net cash provided by (used in) operating activities 25 (4,043) Cash flows from investing activities: Purchases of property, plant and equipment (226) (180) Purchase of intellectual property -- (1,600) Proceeds from sale of property, plant and equipment 200 -- Net cash used in investing activities (26) (1,780) Cash flows from financing activities: Payments on capital lease and note obligations (571) (618) Proceeds from exercise of stock options 4 464 Net cash used in financing activities (567) (154) Net decrease in cash and cash equivalents (568) (5,977) Cash and cash equivalents, beginning of period 25,559 11,484 Cash and cash equivalents, end of period $24,991 $5,507
Regeneration Technologies, Inc.
CONTACT: Thomas F. Rose, Chief Financial Officer, or Wendy Crites Wacker,APR, Corporate Communications, both of Regeneration Technologies,+1-386-418-8888; or Susan A. Noonan, The SAN Group, LLC, +1-212-966-3650,for Regeneration Technologies
Web site: http://www.rtix.com/
